Next Article in Journal
Cognitive and Behavioral Consequences of Sleep Disordered Breathing in Children
Previous Article in Journal
Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
Previous Article in Special Issue
Cytokine Signaling in Multiple Sclerosis and Its Therapeutic Applications
Article Menu

Export Article

Open AccessReview
Med. Sci. 2017, 5(4), 29; doi:10.3390/medsci5040029

Alzheimer’s Disease, Brain Injury, and C.N.S. Nanotherapy in Humans: Sonoporation Augmenting Drug Targeting

Cavitation-Control Technology Inc., Farmington, CT 06032, USA
Present address: Cav-Con Inc., Bellevue, WA 98007, USA.
Received: 29 September 2017 / Revised: 16 November 2017 / Accepted: 20 November 2017 / Published: 24 November 2017
(This article belongs to the Special Issue Advances in the Pathogenesis of Neurodegenerative Diseases)
View Full-Text   |   Download PDF [243 KB, uploaded 27 November 2017]

Abstract

Owing to the complexity of neurodegenerative diseases, multiple cellular types need to be targeted simultaneously in order for a given therapy to demonstrate any major effectiveness. Ultrasound-sensitive coated microbubbles (in a targeted nanoemulsion) are available. Versatile small-molecule drug(s) targeting multiple pathways of Alzheimer’s disease pathogenesis are known. By incorporating such drug(s) into the targeted lipid-coated microbubble/nanoparticle-derived (LCM/ND) lipid nanoemulsion type, one obtains a multitasking combination therapeutic for translational medicine. This multitasking therapeutic targets cell-surface scavenger receptors (mainly scavenger receptor class B type I (SR-BI)), making it possible for various Alzheimer’s-related cell types to be simultaneously sought for localized drug treatment in vivo. Besides targeting cell-surface SR-BI, the proposed LCM/ND-nanoemulsion combination therapeutic(s) include a characteristic lipid-coated microbubble (LCM) subpopulation (i.e., a stable LCM suspension); such LCM substantially reduce the acoustic power levels needed for accomplishing temporary noninvasive (transcranial) ultrasound treatment, or sonoporation, if additionally desired for the Alzheimer’s patient. View Full-Text
Keywords: Alzheimer’s disease; drug targeting; nanoemulsion; neuroinflammation; neurotrauma; oxidative stress; scavenger receptors; SR-BI; transcranial sonoporation Alzheimer’s disease; drug targeting; nanoemulsion; neuroinflammation; neurotrauma; oxidative stress; scavenger receptors; SR-BI; transcranial sonoporation
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

D’Arrigo, J.S. Alzheimer’s Disease, Brain Injury, and C.N.S. Nanotherapy in Humans: Sonoporation Augmenting Drug Targeting. Med. Sci. 2017, 5, 29.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Med. Sci. EISSN 2076-3271 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top